首页> 外文期刊>Indian drugs >FORMULATION AND EVALUATION OF FAST DISSOLVING FILM OF FOSINOPRIL
【24h】

FORMULATION AND EVALUATION OF FAST DISSOLVING FILM OF FOSINOPRIL

机译:FOSINOPRIL快速溶解薄膜的制剂和评价

获取原文
获取原文并翻译 | 示例
           

摘要

The mouth dissolving film overcomes the shortfalls of conventional quick dispersing/dissolving intraoral tablets. Fosinopril is an angiotensin converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of chronic heart failure.lt undergoes extensive hepatic first pass metabolism, with bioavailability being only 36%. In the present investigation, an attempt was made to formulate fast dissolving film of fosinopril sodium by Solvent casting method using various film forming polymers such as HPMC 5cps, HPMC E-3, HPMC E-15 each being varied at three different concentration(6%,8%,10%). Drug-excipient compatibility studies were carried out by FTIR spectroscopy and DSC. in order to establish compatibility between drug and excipients The results revealed that the drug and excipients were satisfactorily compatible, without any significant changes in the chemical nature of the drug. Prepared films were subjected to different evaluation parameters such as folding endurance, physical appearance, %moisture absorption,drug content uniformity, in vitro disintegration time, in vitro dissolution studies and stability studies. All the formulations show name accurred compliance with pharmacopoeial standards. The stability study shows that no significant changes in films after one month study. Results revealed that the formulations F1 containing 6% HPMC 5cps showed better release property, low disintegration time, good folding endurance and good physical appearance compared to other formulations, so it was selected as the best formulation.
机译:口腔溶解膜克服了传统快速分散/溶解口内片的短缺。 Fosinopril是一种血管紧张素转换酶(ACE)抑制剂,用于治疗高血压和某些类型的慢性心力衰竭.LT经历广泛的肝脏首次通过代谢,生物利用度只有36%。在本发明的研究中,通过使用各种膜形成聚合物如HPMC 5CPS,HPMC E-3,HPMC E-15,通过溶剂浇铸方法制备尝试通过溶剂浇铸方法,每个膜形成聚合物,HPMC E-3,HPMC E-15各自以三种不同的浓度变化(6% ,8%,10%)。通过FTIR光谱和DSC进行药物赋形剂相容性研究。为了建立药物和赋形剂之间的相容性,结果表明,药物和赋形剂令人满意地相容,没有药物的化学性质的任何显着变化。对制备的薄膜进行不同的评价参数,如折叠耐久性,物理外观,减轻湿度吸收,药物含量均匀性,体外崩解时间,体外溶解研究和稳定性研究。所有配方展示了名称准确遵守药典标准。稳定性研究表明,在一个月的研究后,薄膜没有显着变化。结果表明,与其他配方相比,含有6%HPMC 5CP的配方F1含有6%HPMC 5CP的释放性能,低崩解时间,良好的折叠耐久性和良好的物理外观,因此选择其作为最佳配方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号